Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomes
Autor: | Mohammadhosein Akhlaghpasand, Maryam Hafizi, Maryam Oraee-Yazdani, Saeed Oraee-Yazdani, Maryam Golmohammadi, Nima Mohseni Kabir, Masoud Soleimani, Alireza Zali, Mina Soufi Zomorrod, Farzad Ashrafi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Medicine (General)
Cell- and Tissue-Based Therapy Medicine (miscellaneous) QD415-436 Mesenchymal Stem Cell Transplantation Transplantation Autologous Biochemistry Biochemistry Genetics and Molecular Biology (miscellaneous) R5-920 Bone Marrow Subacute complete spinal cord injury medicine Humans Schwann cells Spinal cord injury Spinal Cord Injuries Spinal Cord Regeneration Combination cell therapy medicine.diagnostic_test business.industry Research Mesenchymal Stem Cells Magnetic resonance imaging Cell Biology medicine.disease Spinal cord Transplantation medicine.anatomical_structure Anesthesia Molecular Medicine Bone-marrow-derived mesenchymal stem cell Bone marrow Stem cell business Syringomyelia |
Zdroj: | Stem Cell Research & Therapy Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-15 (2021) |
ISSN: | 1757-6512 |
Popis: | Background Cellular transplantations have promising effects on treating spinal cord injury (SCI) patients. Mesenchymal stem cells (MSCs) and Schwann cells (SCs), which have safety alongside their complementary characteristics, are suggested to be the two of the best candidates in SCI treatment. In this study, we assessed the safety and possible outcomes of intrathecal co-transplantation of autologous bone marrow MSC and SC in patients with subacute traumatic complete SCI. Methods Eleven patients with complete SCI (American Spinal Injury Association Impairment Scale (AIS); grade A) were enrolled in this study during the subacute period of injury. The patients received an intrathecal autologous combination of MSC and SC and were followed up for 12 months. We assessed the neurological changes by the American Spinal Injury Association’s (ASIA) sensory-motor scale, functional recovery by spinal cord independence measure (SCIM-III), and subjective changes along with adverse events (AE) with our checklist. Furthermore, electromyography (EMG), nerve conduction velocity (NCV), magnetic resonance imaging (MRI), and urodynamic study (UDS) were conducted for all the patients at the baseline, 6 months, and 1 year after the intervention. Results Light touch AIS score alterations were approximately the same as the pinprick changes (11.6 ± 13.1 and 12 ± 13, respectively) in 50% of the cervical and 63% of the lumbar-thoracic patients, and both were more than the motor score alterations (9.5 ± 3.3 in 75% of the cervical and 14% of the lumbar-thoracic patients). SCIM III total scores (21.2 ± 13.3) and all its sub-scores (“respiration and sphincter management” (15 ± 9.9), “mobility” (9.5 ± 13.3), and “self-care” (6 ± 1.4)) had statistically significant changes after cell injection. Our findings support that the most remarkable positive, subjective improvements were in trunk movement, equilibrium in standing/sitting position, the sensation of the bladder and rectal filling, and the ability of voluntary voiding. Our safety evaluation revealed no systemic complications, and radiological images showed no neoplastic overgrowth, syringomyelia, or pseudo-meningocele. Conclusion The present study showed that autologous SC and bone marrow-derived MSC transplantation at the subacute stage of SCI could reveal statistically significant improvement in sensory and neurological functions among the patients. It appears that using this combination of cells is safe and effective for clinical application to spinal cord regeneration during the subacute period. |
Databáze: | OpenAIRE |
Externí odkaz: |